<DOC>
	<DOCNO>NCT01710501</DOCNO>
	<brief_summary>This study design compare safety efficacy 3 different dos grazoprevir ( MK-5172 ) combine pegylated interferon alfa-2b ( PEG-IFN ) ribavirin ( RBV ) treatment-naïve participant genotype 1 ( GT1 ) chronic hepatitis C ( CHC ) . Participants receive 12 week treatment grazoprevir combine Peg-IFN RBV , depend response Week 4 may go receive additional 12 week treatment Peg-IFN RBV .</brief_summary>
	<brief_title>A Study Different Doses Grazoprevir ( MK-5172 ) Given With Pegylated Interferon Alfa-2b Ribavirin Treatment-Naïve Participants With Chronic Hepatitis C ( MK-5172-038 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Treatment naive Chronic , compensate HCV GT1 infection Absence ( medical history physical finding ) ascites , bleed esophageal varix , hepatic encephalopathy , sign symptom advance liver disease , cirrhosis No evidence cirrhosis hepatocellular carcinoma biopsy noninvasive testing ( e.g . FibroScan and/or FibroTest ) Must agree use two acceptable method birth control least 2 week prior first dose continue least 6 month last dose study drug , longer dictate local regulation NonGT1 HCV infection , include mixed GT infection ( nonGT1 ) nontypeable genotype . Documented Human Immunodeficiency Virus ( HIV ) positive coinfected hepatitis B virus Hepatocellular carcinoma ( HCC ) evaluation HCC Participating participate study investigational compound device within 30 day sign informed consent Diabetic and/or hypertensive clinically significant ocular examination finding Current history central nervous system trauma , seizure disorder , stroke transient ischemic attack Chronic pulmonary disease Current history clinically significant cardiac abnormalities/dysfunction Active clinical gout within last year History gastric surgery history malabsorption disorder Active suspected malignancy , history malignancy , within last 5 year ( except adequately treat carcinoma situ basal cell carcinoma skin ) Pregnant , lactating , expect conceive donate egg , male participant planning impregnate provide sperm donation female partner pregnant Current moderate severe depression history depression associate hospitalization , electroconvulsive therapy , severe disruption daily function , suicidal homicidal ideation and/or attempt , history severe psychiatric disorder Evidence history chronic hepatitis cause HCV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>